MENLO PARK, Calif., December 5, 2013 - Geron Corporation (GERN) today announced that management will be hosting a live webcast of an analyst and investor meeting at 6:30 p.m. CT on December 9, 2013. John A. Scarlett, M.D., Geron`s President and Chief Executive Officer, will discuss the data presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition from the investigator-sponsored study (IST) of imetelstat in myelofibrosis being conducted at Mayo Clinic, Rochester, MN. The audio and slide presentation can be accessed at www.geron.com on the Investor Relations pages, under Events. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.
As previously announced, data from the myelofibrosis IST will be presented by the study investigator, Dr. Ayalew Tefferi, Mayo Clinic, at ASH in a presentation entitled, "Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions in Myelofibrosis and Reversal of Bone Marrow Fibrosis". The investigator`s presentation is scheduled to occur during the Myeloproliferative Syndromes: Clinical: Novel Therapeutic Strategies session on Monday, December 9, 2013 at 4:45 p.m. CT in Theater C.
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
Anna Krassowska, Ph.D.
Investor and Media Relations
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Geron Corp. via GlobeNewswire
- Investment & Company Information
- Geron Corporation
- American Society of Hematology